New Treatment Is Approved for a Variety of Respiratory Infections

JULY 01, 2004
Susan Farley

The FDA recently approved telithromycin to treat acute exacerbation of chronic bronchitis, acute bacterial sinusitis, and mild-to-moderate community-acquired pneumonia in patients aged 18 and older. The drug is manufactured by Aventis under the brand name KETEK. According to Paul Iannini, MD, clinical professor of medicine at Yale University, "KETEK's innovative mechanism of action selectively targets common respiratory pathogens, including resistant strains, without significant effects on bacteria not normally involved in RTIs [respiratory tract infections]. This may be an important factor in minimizing the development of antibiotic resistance, a critical public health concern and one that I've seen in my clinical practice."

KETEK was first introduced in Europe, Latin America, and Asia and has been prescribed for >7 million patients. In its clinical trials, subjects taking KETEK reported side effects such as nausea, headache, dizziness, vomiting, and diarrhea.



SHARE THIS SHARE THIS
0

Immunization Laws Around the Nation

Many areas of medicine that intersect with law and immunizations are associated with a very specific set of laws across the nation.  

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.